Bioequivalence of vildagliptin/metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 5, 2008, Pages 259-267

  He, Yan Ling ^a   Paladini, S ^b   Sabia, H ^b   Campestrini, J ^c   Zhang, Y ^b   Leon, S ^a   Ligueros Saylan, M ^b   Jarugula, V ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NOVARTIS PHARMA K K   (Japan)

Author keywords

Bioequivalence; DPP 4 inhibitor; Incretin; Type 2 diabetes; Vildagliptin

Indexed keywords

METFORMIN; METFORMIN PLUS VILDAGLIPTIN; VILDAGLIPTIN;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; SINGLE DRUG DOSE; SORE THROAT; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 43449109228     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp46259     Document Type: Article

References (21)